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Abstract: The availability of a once-a-year zoledronic acid infusion heralds a new era in
the management of osteoporosis. It virtually eliminates the problem of poor compliance with
orally administered bisphosphonates and, because it bypasses the gastrointestinal tract, it is
not associated with gastrointestinal side effects. Zoledronic acid is effective for the treatment
and prevention of postmenopausal osteoporosis, and for the treatment of osteoporosis in
men, and glucocorticoid-induced osteoporosis. When administered within three months of
a hip fracture, it reduces mortality and the risk of subsequent fractures. It is remarkably free
of serious adverse effects. After administration of the intravenous infusion, about 18% of
bisphosphonate-naïve patients experience an acute-phase reaction, including low-grade temperature, aches, and pains. This is reduced to about 9% in those who have been treated with
oral bisphosphonates, and is further reduced by the concomitant and subsequent administration
of acetaminophen. The likelihood and magnitude of the acute-phase reaction is less after the
second infusion. Other adverse effects are similar to those encountered with other bisphosphonates. Because it is mostly excreted by the kidneys, zoledronic acid should not be administered
to patients with a creatinine clearance less than 35 mL/min. It should not be administered to
patients with hypocalcemia.
Keywords: zoledronic acid, zoledronate, osteoporosis, osteopenia, bisphosphonates
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The main problem with osteoporosis is that it is a silent disease, frequently unnoticed
until a fracture occurs. There are no warning signs. Unfortunately, an osteoporotic
fracture is often a life-changing event, and the mortality and morbidity associated
with fractures, especially at the hip, is considerable. Regrettably, even under the best
circumstances, many patients who have sustained osteoporotic fractures, especially at the
hip, are not able to resume their daily activities. Osteoporosis is characterized by a low
bone mass and microarchitectural deterioration, resulting in an increased susceptibility
to fractures. It is very common, with about 40% of white women and 13% of white men
aged 50 and older expected to sustain an osteoporotic fracture.1–3
The prevalence of osteoporotic fractures in women exceeds the combined prevalence
of breast cancer, stroke, heart failure, and myocardial infarction in women.4 The estimated economic impact of osteoporosis-related fractures is staggering. In the US in
2005, over two million fractures were sustained, costing about $17 billion. About 70%
of these fractures occur in people aged 65 years and older, and these are responsible
for about 87% of the total cost.5
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Diagnosis of osteoporosis
Diagnosis of osteoporosis can be established solely based on
the presence of fragility, low-trauma, or atraumatic fractures.
A fragility fracture is defined as a fracture sustained after
falling from a height that does not exceed the body height.
Low-trauma or low-energy fractures occur after trauma
that would not have been anticipated to result in a fracture.
Atraumatic fractures occur spontaneously in the absence
of trauma, as may happen while the person is sitting down
and suddenly experiences very severe localized back pain
as a result of a vertebral compression fracture. It is also
possible that, in some instances, an atraumatic hip fracture is
responsible for the fall a patient with osteoporosis sustains, as
opposed to the fall causing the fracture. It has been suggested
that the torque force applied to the femoral neck while the
patient is turning may be enough to induce a hip fracture.
Many vertebral compression fractures are asymptomatic,
and the patient presents with no severe back pain, only loss
of height or kyphosis. The presence of these asymptomatic
vertebral compression fractures, however, is also diagnostic
of osteoporosis and substantially increases the risk of
subsequent vertebral and other fractures.
Osteoporosis can also be diagnosed by bone densitometry
of the hip, lumbar vertebrae, or the radius (distal one-third) as
per World Health Organization (WHO) guidelines.6 A T-score
of -2.5 or lower establishes the densitometric diagnosis of
osteoporosis. The T-score refers to the number of standard
deviations the patient’s bone mineral density (BMD) is from
the mean compared with that of a healthy young adult reference population of the same gender. Patients with a T-score of
-1.0 or higher are classified as having a normal bone density,
and those with a T-score less than -1.0 and higher than -2.5
are classified as having osteopenia.
Patients with osteopenia also have an increased fracture risk.
It is, however, intuitive that a patient with a T-score of -2.4 has
a higher fracture risk than one with a T-score of -1.1, although
both are in the same diagnostic category of osteopenia. To
estimate the fracture risk better, the WHO released its Fracture
Risk Assessment (FRAX®) tool in February 2008. This tool
estimates the probability of an osteopenic patient sustaining
a hip or a major osteoporotic fracture within the following 10
years. This probability, expressed as a percentage, is determined based on the BMD and a series of risk factors including
current cigarette and alcohol use, glucocorticoid usage, and
other factors.7 The FRAX® tool is freely available, at no cost,
on the Internet. The National Osteoporosis Foundation has
issued guidelines recommending that treatment be considered
in patients with osteopenia if a threshold is reached, ie, a 3%
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and 20% probability of sustaining a hip or other major fractures, respectively, within the following 10 years.8
The ease of diagnosing osteoporosis and selecting patients
who need to be treated, and the availability of medication
that can significantly alter the natural course of osteoporosis
and substantially reduce the fracture risk, mandate that an
all-out effort be made to identify patients at risk of sustaining
fractures before they actually sustain a fracture. Regrettably,
however, many patients who have sustained an osteoporotic
hip fracture and had it surgically repaired are not treated
for osteoporosis, even though the increased risk of subsequent fractures is well known. The American Orthopaedic
Association has developed the Own the Bone® program in
an attempt to remedy this situation.9

Osteoporosis medications
Patients needing treatment
The final decision to treat or not to treat, and which particular
therapy to use, must be the treating clinician’s decision, based
on the circumstances and needs of the patient. However, as
a general rule, it is recommended that the following receive
medical treatment:
• Patients with fragility fractures
• Patients with a densitometric diagnosis of osteoporosis
(T-score -2.5 or lower at the total hip, femoral neck,
lumbar vertebrae, or distal one-third radius)
• Patients with osteopenia and a FRAX® score of $3%
or $20% for hip and other major osteoporotic fractures,
respectively.
Secondary causes of osteoporosis should first be identified
and corrected, especially hypovitaminosis D. For optimum
results, in addition to specific medications, the therapeutic
strategy must include an adequate daily calcium and vitamin D
intake, as well as lifestyle changes, such as physical exercise
for sedentary patients and the discontinuation of cigarette
smoking in smokers. In older patients, the fracture risk is
reduced and overall outcome is improved by reducing the
risk and impact of falling. Hip protectors may be a useful
tool in this arena.

Compliance with medication
for an asymptomatic condition
One important issue to consider is the patient’s compliance
with long-term intake of a medication for an essentially
asymptomatic condition. The very low bioavailability of
orally administered bisphosphonates necessitates a stringent
routine that often interferes with the patient’s regular daily
routine, ie, the patient must take the oral bisphosphonate
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while fasting, with a glass of water, and must refrain from
eating, drinking, taking any other medication, lying down,
or undertaking any activity that may increase the risk of
gastroesophageal reflux, for 30 minutes (alendronate or
risedronate) or 60 minutes (ibandronate).
Many patients will not comply with this regimen, especially given that patients may often have other medications
that need to be taken in the fasting state. Compliance is also
low in patients who experience adverse effects, such as the
upper gastrointestinal symptoms commonly associated with
oral bisphosphonates. Patients with cognitive impairment
also may not be able to take the medication exactly as
directed. Similarly, in nursing homes and other institutions, it
may not be possible to expect the nursing staff to ensure that
all patients take the bisphosphonate exactly as they should.
There are ample data to support the poor compliance of
patients with intake of oral bisphosphonates and the direct
correlation between compliance and improved outcome.10–12
The US Surgeon General has indeed i dentified poor
c ompliance with therapy as a major obstacle in the
successful management of osteoporosis and reducing the
risk of fractures.13 Patients prefer less frequent dosing
regimens and intravenous (IV) infusion to the oral intake of
bisphosphonates.10,14 These are now becoming available.

Chemical structure
of bisphosphonates
All bisphosphonates share the same basic chemical structure of
two phosphonic acid molecules linked to a carbon molecule.
They also have two side chains which determine the affinity
of the bisphosphonate for the calcium phosphate in hydroxyapatite crystals in bone tissue, and determine the extent to
which the bisphosphonate inhibits the bone-resorbing activity
of osteoclasts by selectively inhibiting the farnesyl pyrophosphate synthase (FPPS) enzyme, the key regulatory enzyme
in the mevalonic acid pathway. This prevents downstream
protein prenylation which, in turn, inhibits the bone-resorbing
activity of osteoclasts, and leads to osteoclast apoptosis. It also
interferes with the formation of osteoclasts.15 Differences in
these two side chains are responsible for the clinical difference
observed between the various bisphosphonates. The affinity of
zoledronic acid for hydroxyapatite is higher than that of other
bisphosphonates, and the inhibition of FPPS is higher than that
seen in other bisphosphonates.16

Zoledronic acid
Zoledronic acid has a nitrogen-containing heterocyclic ring
as a side chain, and can be administered by IV infusion once
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a year, virtually eliminating compliance issues. Improved
compliance is associated with improved fracture protection.17
A cost-effectiveness study conducted in France documented
that over a three-year period, zoledronic acid was more
cost-effective than current therapeutic strategies when
medication cost, medical visits, monitoring, and fracture
management are all taken into consideration.18

Pharmacokinetics
Maximum plasma concentrations of zoledronic acid are
reached, as expected, at the end of the IV infusion. Blood
levels then rapidly decline to less than 10% at four hours
and to less than 1% at 24 hours after infusion. About 61%
of the administered dose is taken up rapidly by bone tissue,
tending to localize in areas of increased turnover rate, and is
then slowly released back into the circulation. The remaining
39% is excreted unchanged via glomerular filtration by
the kidneys without a significant component of tubular
secretion.19 The elimination of zoledronic acid is triphasic,
comprising two rapid phases followed by a long terminal
elimination half-life of 146 hours.15,20
Zoledronic acid clearance is dependent on the patient’s
creatinine clearance. When compared with subjects having
normal renal function (creatinine clearance above 80 mL/min),
the area under the concentration curve is about 15% higher
in patients with mild renal impairment (creatinine clearance
50–80 mL/min) and 43% higher in those with moderate renal
impairment (creatinine clearance between 30–50 mL/min).
Zoledronic acid administration is not recommended in
those with a creatinine level below 35 mL/min. There is no
need to adjust the dose in patients who have a creatinine
clearance of 35 mL/min or higher. Zoledronic acid does not
inhibit the P450 enzyme, and there is therefore no interaction with other medications metabolized via cytochrome
P450.21 However, caution should be exercised in patients
on medications that have the potential of reducing the serum
calcium level, such as loop diuretics and aminoglycosides,
and potentially nephrotoxic medications, such as nonsteroidal
anti-inflammatory compounds.

Pharmacodynamics
Zoledronic acid selectively inhibits the FPPS enzyme,
which leads to a loss of prenylated proteins in osteoclasts
and reduced bone resorbing activity.22 This is manifested by
a reduced concentration of bone resorption markers in the
serum and urine.
A subset analysis of patients included in the Health
Outcomes and Reduced Incidence with Zoledronic Acid
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Once Yearly-Pivotal Fracture Trial (HORIZON-PFT) showed
that when compared with placebo, annual IV infusion of
zoledronic acid induced a median decrease of 50% in betaC-terminal telopeptides of Type 1 collagen (beta-CTx) and
a 30% decrease in bone-specific alkaline phosphatase (ALP)
in 604 patients (305 on placebo and 299 on zoledronic acid),
and a 56% decrease in procollagen Type 1 amino-terminal
peptides (PINP) in 1245 patients (627 on placebo and 618 on
zoledronic acid). In most patients these levels remained
within the premenopausal range before the next infusion.
Levels below the premenopausal range, however, were seen in
1.7%, 17.8%, and 19% for ALP, CTx, and PINP, respectively.
The third infusion of zoledronic acid led to a 60% reduction of
CTx levels within 9–11 days; this was followed by a gradual
increase, indicating the persistence of bone resorption in
patients receiving zoledronic acid. No association could be
found between low PINP levels at the end of the first year
and fracture risk.23
In another subset of the HORIZON-PFT, 152 patients
underwent a bone biopsy at three years. Compared with
placebo, patients receiving zoledronic acid had a higher trabecular number, higher trabecular bone volume, decreased
trabecular separation, and a trend toward improvement in
connectivity density. There were no signs of adynamic bone
tissue.24

Clinical efficacy
Postmenopausal osteoporosis
Zoledronic acid is effective at reducing the risk of fractures
in women with postmenopausal osteoporosis (Table 1). Over
a three-year period, the HORIZON-PFT demonstrated a
41% reduction in the cumulative incidence of hip fractures
(P = 0.0024), a 70% reduction of new morphometric vertebral
fractures (P , 0.001), and a 25% reduction in nonvertebral
fractures (P , 0.001, see Figure 1).25
Compared with placebo, the changes in BMD induced
by zoledronic acid were 6%, 5.1%, and 6.7% in the total hip,
femoral neck, and lumbar vertebrae, respectively. Similarly,
compared with placebo, the biochemical markers of bone
turnover were significantly reduced in the zoledronic acid
group. At 12 months, the levels of serum CTx, bone-specific
ALP, and N-terminal propeptide of Type I collagen were 59%,
30%, and 58% lower, respectively, in the zoledronic acid group
than in the placebo group (P , 0.001 for all groups).25
The HORIZON-PFT was a double-blind, randomized,
placebo-controlled study which included 7736 postmenopausal women between the ages of 65 and 89 years recruited
from 239 clinical centers in 27 countries. Patients included in
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the trial either had a T-score of -2.5 or lower at the femoral
neck or a T-score of -1.5 or lower, in addition to radiological
evidence of either one moderate vertebral compression fracture or two mild vertebral compression fractures.
Patients were randomly allocated to either a placebo
or an active group (zoledronic acid 5 mg) administered by
IV infusion at baseline, year 1, and year 2. The follow-up
period was three years. There were two subgroups of patients;
in the first (3045 active and 3039 placebo), no concomitant
osteoporosis therapy was allowed, and in the second
(830 active and 822 placebo), selective estrogen receptor
modulators, calcitonin, hormonal replacement therapy, or
tibolone were allowed at baseline and during the study.
A subgroup analysis of postmenopausal women aged
75 years and older included in the HORIZON-PFT study
showed that zoledronic acid leads to a significant reduction in
clinical fractures, emphasizing the effectiveness and potential
role of zoledronic acid in the management of osteoporosis
in older patients.26
Although no head-to-head study with fractures as the
endpoint has been conducted, the efficacy of zoledronic acid
in reducing hip fractures has been established.27,28

Glucocorticoid-induced osteoporosis
The HORIZON-PFT glucocorticoid-induced osteoporosis
(GIO) trial29 was a noninferiority study comparing zoledronic
acid with oral risedronate, which demonstrated that, at the end
of a one-year follow-up period, zoledronic acid was not inferior
to oral risedronate (5 mg daily orally) in the prevention and
treatment of GIO (Table 1). The primary endpoint was the
percentage change in BMD at the lumbar spine. Secondary
endpoints included the change in BMD at the proximal femur
and distal radius, and changes in biochemical bone markers.
Two subgroups of patients were included in this study, ie,
those who had been on glucocorticoids for three months or
less (prevention subgroup) and those who had been on glucocorticoids for more than three months (treatment subgroup).
In the latter subgroup, 545 subjects were included (368
women and 177 men) of mean age 53.0 (± 13.8) years; in the
prevention subgroup 288 subjects were included (200 women
and 88 men) of mean age 57.2 (± 15.1) years. Overall, 93%
of the enrolled subjects completed the study.
Zoledronic acid increased BMD at the lumbar
vertebrae more than risedronate in both the treatment
subgroups (by 4.06%, standard error of measurement
[SE] 0.28 versus 2.71%, SE 0.28) and in the prevention
subgroup (2.60%, SE 0.45 versus 0.64%, SE 0.46). Other
bones scanned also showed that zoledronic acid was
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A Morphometric vertebral fracture
Placebo

Zoledronic acid

Patients with new vertebral
fracture (%)

15
Relative risk, 0.30
P < 0.001
10.9%

Relative risk, 0.29
P < 0.001

10

7.7%

5

Relative risk, 0.40
P < 0.001
3.7%

3.3%
2.2%

1.5%
0
0–2

0–1

0–3

Year
C Nonvertebral fracture
3
Hazard ratio, 0.59 (95% Cl, 0.42–0.83)
P = 0.002
2
Placebo
1

Zoledronic acid

0

6

0

12

18

24

30

Cumulative incidence (%)

Cumulative incidence (%)

B Hip fracture

12
Hazard ratio, 0.75 (95% Cl, 0.64–0.87)
P < 0.001
9
Placebo
6
Zoledronic acid
3

0

36

0

6

12

Month
3875
3861

3807
3806

3674
3694

3553
3577

3494
3499

3387
3397

3161
3144

Cumulative incidence (%)

D Any clinical fracture
Hazard ratio, 0.67 (95% Cl, 0.58–0.77)
P < 0.001
10

Placebo

5

Zoledronic acid

0

3875
3861

3761
3759

3586
3589

3875
3861

30

36

3428
3423

3335
3299

3201
3151

2956
2892

6

12

18

24

30

3
Hazard ratio, 0.23 (95% Cl, 0.14–0.37)
P < 0.001
2

Placebo

1
Zoledronic acid

0

36

0

6

12

Month
No. at risk
Zoledronic acid
Placebo

24

E Clinical vertebral fracture

15

0

No. at risk
Zoledronic acid
Placebo

Cumulative incidence (%)

No. at risk
Zoledronic acid
Placebo

18

Month

3758
3750

3585
3571

3422
3390

3327
3257

18

24

30

36

3514
3494

3408
3396

3182
3144

Month
3189
3109

2942
2843

No. at risk
Zoledronic acid
Placebo

3875
3861

3814
3809

3689
3704

3568
3576

Figure 1 Incidence of fractures during the 3-year study period.7 The primary end points – the incidence of morphometric vertebral fracture (Panel A) and the 3-year
incidence of hip fracture (Panel B) – are shown for both groups. In Panel A, the 5675 patients in stratum 1 who were included in the analysis underwent radiography at
baseline and at least once during follow up. Any missing data for earlier visits were imputed from later visits, and missing data for later visits were imputed from earlier visits.
The total number of follow up radiographs were 5675 at 1 year, 5308 at 2 years, and 4969 at 3 years. Secondary end points – nonvertebral fracture (Panel C), any clinical
fracture (Panel D), and clinical vertebral fracture (Panel E) – are also shown over a 3-year period. In panels B, C, D, and E, the number of subjects at 36 months is the number
who had closeout visits on or after the start of the 36-month window for visits.
Reproduced with permission from Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med.
2007;356:1809–1822.25 © 2007 Massachusetts Medical Society. All Rights Reserved.

more effective at increasing BMD than risedronate. The
difference between the two treatment groups was evident
at six months. Changes in biochemical markers of bone
resorption demonstrated that zoledronic acid induced a
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more substantial inhibitory effect on bone turnover than
did risedronate.
Although the overall occurrence of adverse effects was
higher in the zoledronic acid group, the frequency of serious
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Table 1 Indications for zoledronic acid based on selected published studies
Indication
Name of study

Postmenopausal
osteoporosis25

Post-hip fracture30

HORIZON-PFT

HORIZON-RFT

Double-blind;
randomized

Double-blind;
randomized

Double-blind, randomized;
non-inferiority

Placebo

Placebo

Risedronate

3

3

1

Study type
Control
Duration (yrs)
Number included
Age (yrs):
mean/range
Inclusion criteria

End point

7,736

2,127
73.0 ± 5.4
73.1 ± 5.34

Placebo
Zoledronate

74.6 ± 9.86
74.4 ± 9.48

Placebo
Zoledronate

Glucocorticoid-induced Osteoporosis20,29
HORIZON-GIO
Prevention

Treatment

288

545

57.2 ± 15.1

53.0 ± 13.8

Glucocorticoid therapy duration

T # −2.5 or
T # −1.5 and vertebral fx

Osteoporotic hip fx in the
previous 3 months

Fractures
Bone mineral density
Bone markers

Fractures
Mortality

Bone mineral density
Bone markers

N/A

Fracture risk
reduction vs
control

Hip fx
Vertebral (morph) fx
New vertebral fx

41%
70%
25%

New clinical fx 35%

BMD vs
control

Total hip
Femoral neck
Lumbar vertebrae

6%
5.1%
6.7%

N/A

Mortality

N/A

#3 months

.3 months

Lumbar vertebrae

28%

Zoledronate 2.6%
Risedronate 0.6%

Zoledronate 4.1%
Risedronate 2.7%
N/A

Abbreviations: HORIZON, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly; PFT, Pivotal Fracture Trial; RFT, Recurrent Fracture Trial; GIO,
Glucocorticoid-Induced Osteoporosis; fx, fracture; LV, lumbar vertebrae; BMD, bone mineral density; N/A, not applicable.

adverse effects was similar in both drug groups. Many of the
patients reported adverse effects associated with zoledronic
acid which occurred during the first few days after the infusion,
and were consistent with the acute-phase reaction associated
with IV administration of large doses of bisphosphonates.
Seven deaths occurred during the trial, including four on
zoledronic acid and three on risedronate; none was attributed
to the study drug. No case of osteonecrosis of the jaw (ONJ)
or of delayed or nonunion of fractures was reported.
Annual infusions of zoledronic acid are effective at
preventing and treating GIO, and have the advantage of
avoiding compliance and other issues associated with the
intake of oral bisphosphonates.

Following hip fracture
Zoledronic acid reduces the rate of fractures in men and women
who have sustained an osteoporotic hip fracture (Table 1).
The HORIZON-Recurrent Fracture Trial (HORIZON-RFT)
studied the effects of administering zoledronic acid to patients
who had recently sustained a hip fracture. In this randomized,
double-blind, placebo-controlled trial, 2127 patients who had
sustained a hip fracture within the past 90 days were randomly
326
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allocated to either placebo (1062 patients, 802 women and
260 men) or zoledronic acid (1065 patients, 817 women and
248 men). Mean ages were 74.6 (± 9.86) years and 74.4 (+ 9.48)
years in the placebo and zoledronic acid groups, respectively.
Patients were followed up for a median of 1.9 years. Compared
with placebo, patients receiving zoledronic acid had a 35%
reduction (P = 0.001) of any new clinical fracture (1.7% and
3.8% in the zoledronic acid and placebo groups, respectively,
P = 0.02) and the rates of new nonvertebral fractures were
7.6% and 10.7% in the zoledronic acid and placebo groups,
respectively (P = 0.03). Overall mortality was also significantly
less in the zoledronic acid than in the placebo group (9.6% and
13.3%, respectively), representing a 28% mortality reduction
(P = 0.01).30
A subsequent analysis of the HORIZON-RFT when the
time interval between fracture repair surgery and administration of zoledronic acid was taken into account revealed that
administration of zoledronic acid two weeks or more after
surgical repair of the fracture was associated with significant reductions in clinical vertebral, nonvertebral, and hip
fractures, as well as increased hip BMD.31 Results of this
study point to the possibility of administering zoledronic
Drug Design, Development and Therapy 2010:4
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acid to patients hospitalized for hip or other osteoporotic
fractures while still in hospital,32 thus significantly improving
compliance and outcome.

years.34 To assess the usefulness of zoledronic acid in
the management of osteopenia, a 24-month, randomized,
double-blind, placebo-controlled trial was conducted in
581 postmenopausal women, 45 years of age or older, with
evidence of osteopenia as manifested by a T-score less than
−1.0 and higher than -2.5. Zoledronic acid was administered just once at the time of randomization to 181 women
and once a year to 198 women, while 202 women received
placebo infusions.
Compared with placebo, women receiving zoledronic acid
showed a significant increase in BMD of +5.18% (95% confidence interval [CI] 4.64–5.71) and +4.42% (95% CI 3.87–4.97)
in those receiving the annual dose and those receiving the
single dose, respectively. Those on placebo infusion sustained
a decrease in the BMD at the lumbar vertebrae of -1.32% (95%
CI 1.85–0.80). Significant increases in hip BMD were also noted
in women receiving zoledronic acid compared with placebo.
As expected, in the women receiving zoledronic acid there was
an initial decrease in markers of bone turnover, followed by a
gradual partial recovery. Zoledronic acid infusions were well
tolerated. The overall incidence of serious adverse events was
similar in the three groups, being 10.9%, 9.4%, and 11.4% in
the group on zoledronic acid once, zoledronic acid annually,
and placebo, respectively. The adverse events were similar to
those noted in other larger trials. As expected, the incidence of
adverse effects was less after the second dose of zoledronic acid.

Men with osteoporosis
Men are not immune to osteoporosis. In fact, the outcome after a
hip fracture tends to be worse in men than in women. Current estimates indicate that in the US there are presently at least 14 million
men with osteoporosis or low bone mass, and that men sustain
about 500,000 osteoporosis-related fractures every year.33
A two-year, noninferiority, randomized, multicenter, double-blind, active-controlled clinical trial which included 302
men with osteoporosis (including osteoporosis secondary to
hypogonadism) with a mean age of 64 (range 25–86) years
showed that zoledronic acid was not inferior to the weekly
oral bisphosphonate used (Table 2). At the end of the twoyear follow-up period, the mean increase in lumbar vertebral
BMD was 6.1% and 6.2% in the zoledronic acid and oral
bisphosphonate groups, respectively. The overall mortality
and adverse effect were comparable in both groups.20

Prevention of postmenopausal
osteoporosis
Zoledronic acid is approved for the prevention of
osteoporosis in women with osteopenia (Table 2). The
dosage is 5 mg administered by IV infusion every two

Table 2 Indications for zoledronic acid, based on selected as yet unpublished studies
Indication
Name of study
Study type
Control

Men20,33
Unpublished

Unpublished

Non-inferiority;
randomized

Double-blind;
randomized

Alendronate*

Placebo

2

2

Duration (yrs)
Number included
Age

Prevention20,34,35

302

224

Mean 64 years
Range 25–86 years

$45 years
Osteopenia
,5 yrs postmenopause

Inclusion criteria
End point

Bone mineral density

N/A

N/A
Zoledronate

Mortality

Osteopenia
$5 yrs postmenopause

Bone mineral density

Fracture risk
Reduction vs control

BMD vs control

357

Zoledronate
Alendronate

6.1%
6.2%

Placebo

LV – 4.0%
Hip – 2.6%
LV – 2.2%
Hip – 2.1%

N/A

Zoledronate

LV – 4.8%
Hip – 2.1%

Placebo

LV – 0.7%
Hip – 1.0%

N/A

*As cited by Piper33 regarding the HORIZON study mentioned in Reclast20 which does not name the active control.

Abbreviations: BMD, bone mineral density; LV, lumbar vertebrae; N/A not available.
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Of note, no case of atrial fibrillation (AF), ONJ, or long-term
negative effect on renal function was reported.35

Bone loss induced by cancer treatment
A number of medications used in the management of cancer
induce bone loss. Osteoporosis may complicate antiestrogen
therapy in women with hormone-sensitive breast cancer and
androgen deprivation therapy in men with prostate cancer.
Zoledronic acid counteracts this bone loss.36 It also reduces
the skeletal-related events associated with bone metastases
in patients with breast or prostate cancer37,38 and, in addition,
may have specific anticancer activity.37
In women with breast cancer, aromatase inhibitors
increase bone turnover and reduce bone mass by about
4%–5% over a two-year period. Compared with tamoxifen,
the risk of fracture is increased by 35%–50% in women treated
with aromatase inhibitors.39 Several studies have documented
the beneficial effect of zoledronic acid in the management of
bone loss resulting from therapy for cancer.40–44
In a study of 93 men with prostate cancer receiving
androgen deprivation therapy, zoledronic acid was shown to
increase BMD significantly compared with placebo, regardless of whether the patients had been on androgen deprivation
therapy for less or more than one year. In the former group
(50 patients), the change in BMD at 12 months was +5.95%
and -3.23% in the zoledronic acid and placebo groups,
respectively (P = 0.0005). Similarly, among those who had
been on androgen deprivation therapy for more than one year,
the changes in BMD at 12 months were +6.08% and +1.58%
in the zoledronic acid and placebo groups, respectively
(P = 0.0005).45 Several other studies have shown comparable
results for efficacy of zoledronic acid in men receiving androgen deprivation therapy.46–49

Other disease states associated with
a low bone mass and osteoporosis
A number of small studies confirm the efficacy of zoledronic
acid in various disease states. Zoledronic acid has been
shown to prevent the bone loss seen in 62 adult patients who
had received a liver transplant for chronic liver disease.50
Zoledronic acid has also been shown to reduce and possibly
reverse the bone loss often incurred by stroke victims who
develop hemiplegia, especially in the paralyzed side.51–53
Additionally, in a study on 30 human immunodeficiency virus
(HIV)-infected patients (27 men and 3 women), zoledronic
acid was effective at managing HIV-associated osteopenia or
osteoporosis.54 Zoledronic acid also significantly improved
the BMD at the lumbar vertebrae and hips of 54 patients
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with monoclonal gammopathy of undetermined significance
and may be effective for the prevention of fractures in these
patients.55 Finally, several small studies have confirmed the
usefulness of zoledronic acid in the management of osteoporosis in patients with thalassemia.56–58

Adverse effects
Acute-phase reaction
The acute-phase reaction is characterized by a low-grade
fever associated with fatigue, malaise, generalized aches
and pains, and, occasionally, bone pain and arthralgia
occurring 24–36 hours postinfusion and gradually subsiding
over the following 2–3 days.59 The acute-phase response is
dose-dependent, and occurs mostly after the first infusion of
zoledronic acid in a bisphosphonate-naïve patient. It is much
less pronounced in subsequent infusions and in patients who
have previously taken oral bisphosphonates.60 Its severity
can also be reduced by administration of acetaminophen
500–1000 mg or paracetamol just before and for 24–48 hours
after the infusion (Figure 2). Administration of nonsteroidal
anti-inflammatory compounds is not routinely recommended
because of the risk of renal impairment. The acute-phase
reaction has also been seen following the administration of
IV and oral bisphosphonates, albeit to a much lesser extent
and degree of severity.61 Patients should be made aware of this
potential adverse effect and advised to take acetaminophen
should symptoms arise.

Musculoskeletal pain
There have been a few reports of patients experiencing severe
incapacitating musculoskeletal pain in the lower back, pelvis,
hips, upper legs, and ribs after taking IV or oral (weekly or
monthly dose, but not daily dose) bisphosphonates.62 The
US Food and Drug Administration (FDA) has issued an
alert to this effect.63 These musculoskeletal pains are different from the acute-phase reaction. Severe musculoskeletal
pain can occur at any time after the administration of the
bisphosphonate, but tends to improve in many patients after
discontinuation of therapy, although it may linger on in some
patients, even after discontinuation.
The exact mechanism of these musculoskeletal pains has
not been delineated. It could be related to vitamin D deficiency
and the compensatory secondary hyperparathyroidism which
maintains a high degree of bone turnover and increases the
uptake of bisphosphonate in bone, resulting in a higher than
average concentration of bisphosphonate in the bone microenvironment. This, in turn, would lead to increased production
of interleukin-6 and other proinflammatory cytokines, which
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Incidence (%)

Horizon-PFT

Pyrexia

Headache

14

Myalgia

Arthralgia

12

Flu-like illness

Placebo values

16

15%

10

8%

8

7%

6%

6
4

2%

2

1%

1%

2%

1%

5%
2%

1%

2%

1%

1%

0

Incidence (%)

12

Horizon-RFT*

10
8

*Patients received acetaminophen up to 72 hours prn
after infusion. This reduced the incidence of
symptoms by ~50%

7%

6
4
2

3%
<1% <1%

<1% 1%

0

3%

2%
<1% <1% 0%

2% 2%

<1% <1%

Annual infusion
1. Data on file. Study ZOL446H2301. Novartis pharmaceuticals corporation.
2. Data on file. Study CZO446L2310. Novartis pharmaceuticals corporation.

Figure 2 Most common adverse events within 3 days after infusion in HORZON PFT and RFT. (Unpublished data. Study ZOL445H2301, Novartis Pharmaceuticals and Study
CZOL446L2310, Novartis Pharmaceuticals).
Notes: HORIZON PFT, Health Outcomes and Reduced incidence with Zoledronic Acid Once Yearly. Pivotal Fracture Trial: RFT, Recurrent Fracture Trial.

will potentiate the effect of elevated interleukin-6 due to
secondary hyperparathyroidism.58,64 Other causes of acute
musculoskeletal pain could be related to bisphosphonateassociated synovitis,65 flare-up of osteoarthritis,66 or acute
polyarthritis and myalgia.67

Arrhythmias and atrial fibrillation
In the HORIZON-PFT, arrhythmias occurred in 6.9%
(n = 266) of patients on zoledronate as compared with 5.3%
(n = 203) patients on placebo (P = 0.003).68 Serious AF was
an unexpected finding, occurring in 50 (1.3%) patients on
zoledronic acid as compared with 20 (0.5%) patients on
placebo (P , 0.001). In 47/50 patients who developed AF,
the event occurred more than 30 days after the infusion,
excluding the possibility that AF was due to hypocalcemia or
other electrolyte disturbance induced by administration of the
bisphosphonate.68
Subsequent studies have shown that other bisphosphonates,
including alendronate, are also associated with AF. More patients
with AF had previously used alendronate (6.5%) than controls
(4.1%, P = 0.03).69 In the HORIZON-RFT, AF was reported
in 2.8% of those receiving zoledronic acid and 2.6% of those
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receiving placebo; similarly, serious AF was reported in 1.1%
and 1.3% of the treatment and placebo groups, respectively.
Because the HORIZON study (like all other pivotal fracture
studies) was not designed to examine the occurrence of AF,
doubt could be cast on the reliability of the reported data on
AF,70 especially given that arrhythmias tend to occur more
frequently in older patients. Possible mechanisms by which bisphosphonates may predispose to AF have been described.68
On 12 November 2008, a press release from the FDA
announced that it could not establish a clear relationship
between bisphosphonate therapy and AF, that health care
professionals should not alter their prescribing habits for
bisphosphonates, and patients should not stop taking these
medications because of concern about AF.71

Nephrotoxicity
Annual infusions of zoledronate over a three-year period did not
result in any significant deterioration of renal function.25,72 There
was nevertheless a transient increase in serum creatinine levels of
more than 0.5 mg/dL in 1.3% of patients on zoledronic acid as
opposed to 0.4% on placebo. Within 30 days, however, the level
in more than 85% of patients had returned to the preinfusion
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level.72 Because approximately one-third of the zoledronic acid
dose administered IV is excreted by glomerular filtration, it is
not recommended to administer this drug to patients who have
a creatinine clearance of less than 35 mL/min. It is also recommended that the IV infusion time be at least 15 minutes.

Atypical fractures
of the femoral diaphysis
There have been several reports of low-trauma fracture of
the femoral shaft in patients who have been on long-term
(2.5–8 years) bisphosphonate therapy.73–77 Bone biopsies
revealed excessive suppression of bone turnover, and healing was delayed or absent in many patients. Most of the
patients who sustain these fractures experience prodromal
thigh pain or vague discomfort for several weeks or months
before the fracture occurs, suggesting that the fracture may
result from the propagation of a stress fracture that has not
been able to heal. The majority of patients who have sustained these fractures also had one or more predisposing
factors, such as chronic corticosteroid use, diabetes mellitus, and severe osteoarthritis of the hip or knee. The
total incidence of these fractures was 2.5 per 100,000
person-years. The incidence, however, was 0.8 per 100,000
person-years in a population aged 15–60 years and 7.8 per
100,000 person-years for people aged 60 years or older. It
has therefore been recommended that patients who have
been on bisphosphonate therapy for longer than two years be
instructed that pain in the groin or upper thigh may be prodromal of a femoral diaphysis fracture and that they should
seek medical help should they experience this pain.60

Bisphosphonate-associated
osteonecrosis of the jaw
Several terms are used to refer to this condition, including
ONJ, bisphosphonate-related ONJ, bisphosphonate-induced
ONJ, and bisphosphonate-associated ONJ. In order to reduce
ambiguity and promote international uniformity, an Expert
Panel of the American Dental Association recommended
use of the term bisphosphonate-associated osteonecrosis of
the jaw (BON).
There is still no consensus on the definition of BON. The
common denominators of the various proposed definitions
include an area of exposed, nonhealing bone in the mandible
or maxilla in patients who have been on bisphosphonates
and have not received radiation therapy to the jaw. The
exposed bone and adjacent area may be asymptomatic or
may become secondarily infected. Patients may present with
pain, swelling, paresthesia, suppuration, soft tissue ulceration
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in tissue adjacent to the ragged bony margins of the lesion,
intra- and extraoral sinus tracks, loosening of the teeth,
and in severe cases, loss of a significant part of the mandible
or maxilla.78 Whereas the American Society for Bone and
Mineral Research (ASBMR), and the American Academy
of Oral and Maxillofacial Surgeons (AAOMS) stipulate
that the bone should be exposed for at least eight weeks, the
American Dental Association (ADA), the Australian and
New Zealand Bone and Mineral Society (ANZBMS) and the
Medical Oncology Group of Australia stipulate that the bone
should be exposed for only six weeks or more. The American
Association of Endodontists and the American College of
Rheumatology do not stipulate any time limit. The majority
of reported cases have followed teeth extraction or other
dental procedures, although a few cases have been reported
to have occurred spontaneously in patients with osteoporosis
treated with oral bisphosphonates.79 The ASBMR task force
recommends first excluding other common conditions, such
as mucositis, gingivitis, periodontal disease, sinusitis, caries
infection, and osteomyelitis.80
The AAOMS has defined three stages of ONJ:78,81
Stage 1, exposed or necrotic bone in asymptomatic patients
with no evidence of infection; Stage 2, superimposed infection as evidenced by pain and erythema in the region of
the exposed bone, with or without purulent drainage; and
Stage 3, same findings as for Stage 2, in addition to pathologic
fracture, extraoral fistula, and/or osteolysis extending to the
inferior border.
The Expert Panel of the ADA79 concluded that, although
still early in the investigative stage, there appears to be a
causal relationship between bisphosphonate exposure and
BON, as evidenced by the strength of the association (the
incidence is higher among individuals on bisphosphonates),
temporal association (exposure to bisphosphonates precedes
BON), biologic gradient (higher doses are associated with
more rapid and serious presentation of BON), consistency
(BON has been reported by several investigators), specificity (BON is seen in patients with cancer, osteoporosis,
and Paget’s disease), and biologic plausibility (BON is
defined by the mechanism of action of bisphosphonates, and
inhibition of angiogenesis and bone formation after dental
extraction).
It is, however, debated whether the initial damage in
ONJ starts in the bone and then spreads to the surrounding
soft tissues (“inside-out” hypothesis), or whether it starts in
the oral epithelium and mucosa, and then spreads to the soft
tissue and eventually to bone (“outside-in” hypothesis).78
Bisphosphonate toxicity to mucosal cells is well known, as
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evidenced by the gastric, esophageal, and even oral erosions
complicating the intake of oral bisphosphonates.82–85 It is
therefore possible that the pathology starts in the oral mucosa
and then spreads to the deeper tissues and bone.
On the other hand, proponents of the inside-out hypothesis suggest that if the rate of bone turnover is substantially
reduced, repair of microfissures may be impaired, and this may
increase susceptibility to bone necrosis. An antiangiogenic
effect of bisphosphonates has been suggested as a possible
mechanism leading to BON, whereby interference with blood
supply may lead to bone necrosis.86 Several studies have
documented that bisphosphonates inhibit angiogenesis.87
While this explanation is plausible for cases affecting the
mandible, it is difficult to explain the relatively frequent
involvement of the maxilla with its rich blood supply; 26%
of cases have involved only maxillary bone, and 9% involved
both the maxilla and mandible.88 It is possible therefore that
the etiology of BON is multifactorial.89
Several cases have been reported, mostly among patients
with cancer treated with large doses of IV bisphosphonates.
A review of 368 BON cases reported in the medical literature
for 1996–2006 showed primary diagnoses of multiple
myeloma (n = 171), metastatic breast cancer (n = 143),
metastatic prostate cancer (n = 23), and other metastatic
neoplasia (n = 13). Only 18 cases occurred in patients without
cancer, ie, three treated for Paget’s disease and 15 treated
for osteoporosis. In other words, in this large series of
368 patients, only 15 (4.1%) had received bisphosphonates
for osteoporosis.88
ONJ, defined as exposed bone in the maxillofacial area
for more than six weeks with delayed healing despite appropriate care, was observed in two of 7714 patients enrolled in
HORIZON-PFT. One patient was in the active group receiving zoledronic acid and the other was in the placebo group.
The condition of both patients improved after appropriate
antibiotic therapy, debridement, or both.90 The investigators
concluded that BON is rare in otherwise healthy postmenopausal osteoporotic women treated with zoledronic acid, and
that there is no evidence to suggest that these patients need
any special treatment beyond routine dental care, or to support
altering standard treatment guidelines. An examination of the
oral cavity before prescribing bisphosphonates is prudent and
does not have to be conducted by a dental professional.
A reduced rate of bone turnover, as evidenced by low
serum bone markers levels, such as serum beta-CTx, may
predispose to ONJ, and therefore assaying these levels may
be helpful in identifying patients susceptible to BON.91 On the
other hand, cases of BON have been reported in patients with
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normal CTx levels,92 and the presently available data do not
support the use of serum CTx to assess the risk of BON.61
The exact risk of developing BON is not known. In a prospective study in Australia where cases were identified based
on the presence of exposed bone for six weeks or more and
verification of drug prescriptions, the incidence associated
with oral alendronate use was in the range 0.01%–0.04%,
and this risk was increased by more than four-fold in patients
undergoing dental extraction. The median time of alendronate
use prior to onset of BON was two years,93 although most
cases occur after prolonged therapy. Risk factors predisposing to BON include advanced age, corticosteroid use,
rheumatoid arthritis, diabetes mellitus, tooth extraction,
invasive dental procedures, and smoking.94 The majority
of reported BON cases occurred in patients receiving large
doses of IV bisphosphonate as part of cancer therapy. The
risk/benefit ratio of BON versus fractures in patients with
osteoporosis is in favor of treating such patients, and this
should be explained to interested patients. In patients who are
about to undergo major dental work, it is prudent to postpone
the initiation of bisphosphonate therapy until after the dental
work has been completed. It is also advisable to examine the
gums prior to initiating bisphosphonate therapy. Several task
forces and expert panels have developed recommendations
for the prevention of BON.81,95,96

Ocular adverse effects
Although rare, ocular inflammation occurs in a small minority of bisphosphonate-treated patients, who may present with
ocular pain, photophobia, and/or impaired vision. Nonspecific
conjunctivitis is usually benign, self-limiting, and improves
without specific therapy.60 Uveitis and scleritis, on the other
hand, are serious complications. Very few cases of posterior scleritis and anterior uveitis complicating zoledronic
acid therapy have been reported.97–101 Ocular complications
are idiosyncratic, and may occur shortly after, or weeks,
months, or even years after the initiation of bisphosphonate
therapy.61,102 Given the potential implications of these conditions, urgent ophthalmologic referral is recommended for
patients who present with eye symptoms.

Hypocalcemia and secondary
hyperparathyroidism
Nitrogen-containing bisphosphonates are potent inhibitors of
osteoclastic bone resorption. By reducing bone resorption,
they reduce the mobilization of calcium from bones to the
circulation. Their administration therefore may lead to
hypocalcemia, which in turn leads to secondary hyperpara-
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thyroidism, which increases renal tubular calcium resorption
and activates the 1-alpha hydroxylase enzyme in the kidneys.
The 25-hydroxyvitamin D in the kidneys is then hydroxylated
to 1,25 dihydroxyvitamin D as a compensatory method of
increasing the gastrointestinal absorption of calcium, thus
restoring serum calcium levels to the normal range.
Patients with hypovitaminosis D, parathyroid dysfunction,
or renal failure may not be able to correct the hypocalcemia,
which then becomes symptomatic. It is therefore important to
ensure that patients about to be administered a bisphosphonate, especially via the IV route, are not vitamin D-deficient
and that they have an adequate daily intake of calcium and
vitamin D. If there are any concerns, it may be prudent to
assay serum 25-hydroxyvitamin D, parathyroid hormone,
calcium, and phosphorus levels. Bisphosphonate-induced
hypocalcemia and secondary hyperparathyroidism may be
avoided or attenuated by the administration of vitamin D
and calcium supplements. Secondary hyperparathyroidism
should be avoided, especially in patients with cancer, because
parathyroid hormone may promote tumor growth.103

Upper gastrointestinal adverse effects
Upper gastrointestinal adverse effects are one of the main
factors limiting the use of oral bisphosphonates. Because
zoledronic acid is IV administered, it bypasses the gastrointestinal tract, so these adverse effects are rarely seen.

Practical points
Indications and dosage
Zoledronic acid is approved for the treatment and prevention
of postmenopausal osteoporosis, osteoporosis in men, GIO,
and prevention of a second hip fracture in patients who have
sustained a first hip fracture. The treatment dose is 5 mg IV
annually, and the prevention dose is 5 mg IV every other year.
Contraindications include:
• Hypocalcemia at the time of infusion
• Hypersensitivity to zoledronic acid, any bisphosphonate,
or any components of zoledronic acid
• Patients with a creatinine clearance less than 35 mL/min
• Pregnant or nursing mothers
• Patients on other forms of zoledronic acid

Administration
Zoledronic acid 5 mg in 100 mL aqueous solution should
be administered by IV infusion via a vented infusion line,
administered over at least 15 minutes. Serum calcium and
creatinine clearance should be checked prior to the infusion.
Patients with hypocalcemia or a creatinine clearance of
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less than 35 mL/min should not receive the infusion. There
is no need to adjust the dose for patients with a creatinine
clearance above 35 mL/min. It is also advisable to assay
the serum 25-hydroxyvitamin level to ensure the patient
does not have hypovitaminosis D. A dental examination
should be performed to ensure that the patient is not in
need of any major dental work. This does not have to be
done by a dental professional. Adequate hydration should
be ensured by instructing the patient to drink at least two
glasses of water or other fluids before the infusion. Patients,
especially bisphosphonate-naïve ones, should be appraised
of the possible acute-phase reaction and alerted that taking
acetaminophen beforehand might minimize these effects.
Administration of acetaminophen following the infusion may
reduce the incidence of the acute-phase reaction. Adequate
hydration should be maintained, as well as an adequate daily
calcium and vitamin D intake.

Conclusions
The availability and effectiveness of annual zoledronate
infusion for the treatment of osteoporosis heralds a new
era in the management of osteoporosis, because it virtually
eliminates the compliance problem. It is especially helpful
if the administration of zoledronic acid can be done at the
same time as the patient undergoes some other medical
check-up or procedure, such as a bone density scan or
mammography.
The positive effect of zoledronate in the prevention of
fractures after the patient has sustained a hip fracture introduces the concept of administering it while the patient is
hospitalized for an osteoporotic fracture. This will reduce the
number of patients who sustain an osteoporotic fracture and
are neither diagnosed nor treated for osteoporosis.
The need for an IV infusion may deter a few patients,
particularly in geographic areas where IV infusions are not
frequently administered, and the patient may need to be
referred to a secondary medical center.
Although no head-to-head fracture trial has been performed,
the efficacy of zolendrate is at least as good, if not superior, to
other treatment modalities. Apart from the acute-phase reaction,
the incidence of adverse effects is relatively low and benign.
Renal functions are maintained, and atrial fibrillation, although a
concern, does not appear to be directly related to the medication.
BON is rare. Patient acceptance of zoledronic acid is good.
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